Vis enkel innførsel

dc.contributor.authorHynnekleiv, Leif
dc.contributor.authorThrane, Alexander Stanley
dc.contributor.authorKrohn, Jørgen
dc.date.accessioned2021-04-27T12:24:46Z
dc.date.available2021-04-27T12:24:46Z
dc.date.created2020-10-27T11:30:04Z
dc.date.issued2020
dc.PublishedBMJ Case Reports. 2020, 13:e235194 (10), 1-3.
dc.identifier.issn1757-790X
dc.identifier.urihttps://hdl.handle.net/11250/2739933
dc.description.abstractAqueous misdirection syndrome is a rare, incompletely understood, sight-threatening eye condition that is difficult to diagnose and treat. We present a case of simultaneous bilateral aqueous misdirection following the administration of certolizumab in a 41-year-old women with rheumatoid arthritis and no known risk factors. To our knowledge, aqueous misdirection has not previously been associated with the use of tumour necrosis factor-alpha inhibitors.en_US
dc.language.isoengen_US
dc.publisherBMJen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleSimultaneous bilateral aqueous misdirection following certolizumab therapy for rheumatoid arthritisen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2020 The Authorsen_US
dc.source.articlenumbere235194en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1136/bcr-2020-235194
dc.identifier.cristin1842554
dc.source.journalBMJ Case Reportsen_US
dc.source.4013:e235194
dc.source.1410
dc.identifier.citationBMJ Case Reports. 2020;13:e235194en_US
dc.source.volume13en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal